Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase
Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage biopharmaceutical firm, will present its CD34+ cell therapy candidate, CLBS119, at the BioNJ COVID-19 Rapid Fire Research Showcase on June 5, 2020. This innovative therapy aims to repair lung damage caused by severe COVID-19 infections. The company is also advancing other cell therapy products, including CLBS12 for critical limb ischemia and CLBS16 for coronary microvascular dysfunction, with various stages of clinical trials underway. Further details about these developments are available on their website.
- CLBS119 aims to repair COVID-19 induced lung damage.
- Presentation at BioNJ COVID-19 Research Showcase raises visibility.
- Ongoing trials for CLBS12 and CLBS16 indicate robust pipeline.
- No current commercial products yet; still in clinical stages.
- Clinical trial results pending for multiple candidates.
BASKING RIDGE, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease today announced that the company has been selected to present at the BioNJ COVID-19 Rapid Fire Research Showcase on Friday, June 5, 2020. David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius Biosciences, will present an overview of CLBS119, Caladrius’ CD34+ cell therapy product candidate targeting repair of COVID-19 induced lung damage.
For more information on BioNJ’s COVID-19 Rapid Fire Research Showcase, please click here.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company's current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming months as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: CLBS12, recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia ("CLI") based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction ("CMD"); and CLBS14, a Regenerative Medicine Advanced Therapy ("RMAT") designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the "FDA") a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina ("NORDA"). For more information on the company, please visit www.caladrius.com.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
FAQ
What is CLBS119 and how does it relate to COVID-19?
When is Caladrius presenting at the BioNJ COVID-19 Research Showcase?
What is the stock symbol for Caladrius Biosciences?
What other therapies is Caladrius developing?
What stage are CLBS12 and CLBS16 in their clinical trials?
